Vertex Pays $10 Billion to Enter Rare Endocrine Disease
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal. The acquisition adds two rare endocrine disease assets—PALSONIFY and Atumelnant—to Vertex's portfolio, expanding its therapeutic focus to include endocrinology. Vertex expects the combined peak annual revenue potential to exceed $5 billion and anticipates the deal to be accretive to non-GAAP operating income by 2029. Both boards approved the transaction unanimously, with closing expected in Q3 2026.
Vertex Pharmaceuticals fell 0.30% in premarket after the cystic fibrosis and pain drug maker announced an all-cash acquisition of Crinetics Pharmaceuticals , a San Diego-based specialty endocrinology company, for $85 per share, or $10 billion in equity value and $8.8 billion net of cash. Both boards approved the deal unanimously. Vertex will fund it from existing cash and $4.5 billion in committed bridge financing, with closing expected in Q3 2026. Crinetics shares rose 99%.
The deal adds two assets to Vertex's portfolio. PALSONIFY is the first and only once-daily oral therapy for acromegaly, a rare growth hormone disorder affecting roughly 20,000 U.S. patients. Atumelnant is an oral ACTH receptor antagonist in Phase 2/3 for congenital adrenal hyperplasia, a rare genetic disease affecting approximately 17,000 U.S. patients.
Vertex projects combined peak annual revenue potential of more than $5 billion from the two assets and expects the acquisition to become accretive to non-GAAP operating income in 2029. The deal adds a fifth disease pillar (endocrinology) alongside cystic fibrosis, pain, hematology, and renal disease.